GSK paid $10.6B for Nuvalent, timing the deal to capitalize on a share dip triggered by disappointing ASCO data.
Endpoints News
GSK’s $10.6 billion buyout of Nuvalent, announced Tuesday, was the largest in the company’s history. But did new CEO Luke Miels get a discount?
endpoints.news
